The present invention is directed to an anti-cancer drug containing an anti-MFG-E8 antibody as an active ingredient, and to an anti-cancer drug which employs an anti-MFG-E8 antibody in combination with a cancer therapy employing an anti-cancer agent other than the anti-MFG-E8 antibody.